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The recruitment of inhibitory GABAA receptors to neuronal synapses requires a complex
interplay between receptors, neuroligins, the scaffolding protein gephyrin and the
GDP-GTP exchange factor collybistin (CB). Collybistin is regulated by protein-protein
interactions at the N-terminal SH3 domain, which can bind neuroligins 2/4 and the
GABAAR α2 subunit. Collybistin also harbors a RhoGEF domain which mediates
interactions with gephyrin and catalyzes GDP-GTP exchange on Cdc42. Lastly,
collybistin has a pleckstrin homology (PH) domain, which binds phosphoinositides,
such as phosphatidylinositol 3-phosphate (PI3P/PtdIns3P) and phosphatidylinositol
4-monophosphate (PI4P/PtdIns4P). PI3P located in early/sorting endosomes has
recently been shown to regulate the postsynaptic clustering of gephyrin and GABAA
receptors and consequently the strength of inhibitory synapses in cultured hippocampal
neurons. This process is disrupted by mutations in the collybistin gene (ARHGEF9),
which cause X-linked intellectual disability (XLID) by a variety of mechanisms converging
on disrupted gephyrin and GABAA receptor clustering at central synapses. Here we
report a novel missense mutation (chrX:62875607C>T, p.R356Q) in ARHGEF9 that
affects one of the two paired arginine residues in the PH domain that were predicted
to be vital for binding phosphoinositides. Functional assays revealed that recombinant
collybistin CB3SH3-R356Q was deficient in PI3P binding and was not able to translocate
EGFP-gephyrin to submembrane microaggregates in an in vitro clustering assay.
Expression of the PI3P-binding mutants CB3SH3-R356Q and CB3SH3-R356N/R357N in cultured
hippocampal neurones revealed that the mutant proteins did not accumulate at inhibitory
synapses, but instead resulted in a clear decrease in the overall number of synaptic
gephyrin clusters compared to controls. Molecular dynamics simulations suggest that
the p.R356Q substitution influences PI3P binding by altering the range of structural
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conformations adopted by collybistin. Taken together, these results suggest that the
p.R356Q mutation in ARHGEF9 is the underlying cause of XLID in the probands,
disrupting gephyrin clustering at inhibitory GABAergic synapses via loss of collybistin
PH domain phosphoinositide binding.
Keywords: ARHGEF9, Collybistin, Gephyrin, PH domain, PI3P, XLID
INTRODUCTION
The Dbl-family guanine nucleotide exchange factor collybistin
was initially identified as an interactor of the inhibitory
postsynaptic clustering protein gephyrin (Kins et al., 2000).
Collybistin exists in several splice isoforms differing in the N-
or C-termini (CB1-CB3), and the presence or absence of an
exon encoding a regulatory SH3 domain (e.g., CB3SH3+, CB2SH3-;
Kins et al., 2000; Harvey et al., 2004). Collybistin variants
lacking the SH3 domain (e.g., CB2SH3-/CB3SH3-) are capable of
forming submembrane gephyrinmicroclusters in cellular models
(Kins et al., 2000; Harvey et al., 2004). By contrast, collybistin
variants containing SH3 domain (e.g., CB2SH3+/CB3SH3+) do
not trigger clustering, but co-localize with gephyrin in large
intracellular aggregates (Kins et al., 2000; Harvey et al., 2004).
Later studies revealed that SH3 domain containing variants adopt
a closed and autoinhibited conformation that largely prevents
membrane binding (Soykan et al., 2014). Since collybistin
variants containing SH3 domains predominate in the brain
and spinal cord (Harvey et al., 2004; Soykan et al., 2014) this
triggered a search for neuronal regulatory proteins that could
bind to the SH3 domain and trigger collybistin activity. This
resulted in the identification of neuroligin-2 (NL2), neuroligin-
4 (NL4) and the GABAA receptor α2 subunit as collybistin
SH3 domain interactors (Poulopoulos et al., 2009; Saiepour et al.,
2010; Hoon et al., 2011). The intracellular domains of these
proteins contain collybistin-binding motifs that interact with the
SH3 domain, triggering collybistin-mediated gephyrin clustering
by conformational ‘‘opening’’ of SH3 domain containing
collybistin variants. Consistent with these findings, knockout
mice lacking collybistin, or collybistin activators, show a brain
region specific loss of gephyrin clusters at inhibitory synapses
and defects in inhibitory synaptic transmission (Papadopoulos
et al., 2007, 2008; Jedlicka et al., 2009, 2011; Poulopoulos et al.,
2009; Hoon et al., 2011; Panzanelli et al., 2011). Disruption of
collybistin-GABAA receptor α2 subunit interactions in mice also
leads to loss of a subset of inhibitory synapses, spontaneous
seizures and early mortality, with surviving animals showing
anxiety-like behavior (Hines et al., 2018).
All known collybistin isoforms also contain tandem RhoGEF
and pleckstrin-homology (PH) domains. The RhoGEF domain
catalyzes GDP-GTP exchange on the small GTPase Cdc42 and
also mediates interactions with gephyrin (Xiang et al., 2006).
However, the role of RhoGEF activity on Cdc42 in gephyrin
clustering is unclear. Gephyrin binding inhibits collybistin
activity on Cdc42 (Xiang et al., 2006) implying that gephyrin
binding inhibits collybistin GDP-GTP exchange. Moreover,
artificial collybistin mutants lacking RhoGEF activity on Cdc42
(T91A, K192A and N232A-N233A) are still capable of inducing
the formation of submembrane gephyrin clusters in transfected
cells and in cultured hippocampal neurons (Reddy-Alla et al.,
2010). Lastly, gephyrin and GABAAR clustering is not affected by
hippocampal deletion of Cdc42 in mice (Reddy-Alla et al., 2010).
By contrast, the PH domain plays a more vital role in clustering,
since deletion of the collybistin PH domain, or mutation of
two key arginine residues (R356/R357) abolishes collybistin-
mediated gephyrin clustering in functional assays (Harvey et al.,
2004; Kalscheuer et al., 2009; Reddy-Alla et al., 2010). This
is because the PH domain and in particular R356/R357 are
key determinants of binding of phosphoinositides, including
phosphatidylinositol 3-phosphate (PI3P/PtdIns3P; Kalscheuer
et al., 2009; Reddy-Alla et al., 2010) and phosphatidylinositol
4-monophosphate (PI4P/PtdIns4P; Ludolphs et al., 2016).
Consistent with this view, PI3P located in early/sorting
endosomes has recently been shown to regulate the postsynaptic
clustering of gephyrin and GABAA receptors and consequently
the strength of inhibitory synapses in cultured hippocampal
neurons (Papadopoulos et al., 2017).
The critical role of collybistin in inhibitory synaptic structure
and function was confirmed by the discovery of missense and
nonsense mutations, deletions and complex re-arrangements
affecting the collybistin gene (ARHGEF9) in patients with
X-linked intellectual disability (XLID; Harvey et al., 2004;
Marco et al., 2008; Kalscheuer et al., 2009; Lesca et al., 2011;
Shimojima et al., 2011; Lemke et al., 2012; de Ligt et al., 2012;
Long et al., 2016; Alber et al., 2017; Klein et al., 2017; Wang
et al., 2018). However, the associated clinical phenotypes vary
significantly, perhaps depending on whether mutant proteins
can act in a dominant-negative manner, or other factors, such
as skewed X-inactivation in females or the involvement of
other nearby genes in chromosomal deletions or rearrangements
(Long et al., 2016; Alber et al., 2017; Aarabi et al., 2018). For
example, a p.G55A mutation in the SH3 domain acted in a
dominant-negative manner, disrupting gephyrin clustering in
transfected cells and neurons by affecting GABAAR α2 subunit
and NL2/NL4 interactions (Harvey et al., 2004; Poulopoulos
et al., 2009; Saiepour et al., 2010; Hoon et al., 2011). This
mutation was associated with hyperekplexia, early infantile
epileptic encephalopathy and severe psychomotor retardation
(Harvey et al., 2004). By contrast, a balanced chromosomal
translocation resulting in collybistin isoforms that lacked a
complete PH domain resulted in disrupted synaptic localization
of endogenous gephyrin andGABAA receptors (Kalscheuer et al.,
2009). This mutation was associated with a disturbed sleep-wake
cycle, increased anxiety and aggressive behavior. However, more
recently a series of missense mutations in ARHGEF9 have
been shown to impact collybistin phosphoinositide binding
(Papadopoulos et al., 2015; Long et al., 2016). These include
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p.R290H and p.R338W missense mutations in the RhoGEF
domain, which were linked to XLID/epilepsy and non-syndromic
(NS)-XLID with variable macrocephaly and macro-orchidism,
respectively. Substitution p.R290H was predicted to alter the
strength of intramolecular interactions between the RhoGEF
and PH domains, while p.R338W was predicted to result
in clashes with adjacent amino acids (K363 and N335) and
disruption of electrostatic potential and local folding of the
PH domain. Thus, both mutations indirectly result in a loss
of PI3P binding affinity and collybistin-mediated gephyrin
clustering (Papadopoulos et al., 2015; Long et al., 2016). In
this study, we report the identification of a novel pathogenic
missense variant in ARHGEF9 using next-generation sequencing
and variant filtering in a family with mild NS-XLID, which
was recently included in a case series (Alber et al., 2017).
The identified mutation (p.R356Q) directly affects one of the
two paired arginine residues in the PH domain that are
vital for binding phosphoinositides. Using a combination of
PI3P binding assays, gephyrin clustering assays, and molecular
dynamics simulations, we present compelling evidence that this
mutation not only disrupts phosphoinositide binding, but also
results in defective gephyrin clustering in both cellular and
neuronal models.
MATERIALS AND METHODS
Exon Capture and DNA Sequencing
X-chromosome exome resequencing and bioinformatics analysis
was performed as recently described (Hu et al., 2014, 2016).
However, for mapping of the 101bp reads BWA (version 0.5.9-
r16, maximal mismatches: -n 5) was applied, partial mapping
was still performed by using SplazerS (Emde et al., 2012).
Genomic DNA from the affected male II:8 was used for
constructing the sequencing library using the Illumina Genomic
DNA Single End Sample Prep kit (Illumina, San Diego, CA,
USA). Enrichment of the X-chromosome exome was then
performed using the Agilent SureSelect Human X Chromosome
Kit (Agilent, Santa Clara, CA, USA). PCR primers for mutation
confirmation and segregation analysis were ARHGEF9-D228F
5’-TTTTTCCTCCAGCTTCTTGG-3’ and ARHGEF9-D228R 5’-
AACCAACCCCCATTGGTACT-3’. This study was carried out
in accordance with the recommendations of the University
of Welfare and Rehabilitation Sciences in Iran with written
informed consent from all subjects. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
The protocol was approved by the University of Welfare and
Rehabilitation Sciences in Iran.
Site-Directed Mutagenesis and Expression
Constructs
Full-length human collybistin (CB) cDNAs were cloned into
the vector pRK5 as previously described (Kalscheuer et al.,
2009). Mutations were introduced into pRK5myc-CB3SH3-
construct using the QuikChange site-directed mutagenesis kit
(Agilent, Santa Clara, CA, USA) and confirmed by Sanger DNA
sequencing of the entire coding region.
PI3P Pull-Down Assays
Affinity purification assays using PI3P agarose beads were
carried out as described previously (Kanamarlapudi, 2014).
Human embryonic kidney 293 (HEK293) cells were grown in
DMEM supplemented with 10% (v/v) fetal bovine serum at
37◦C, 5% CO2 and transfected with 4 µg pRK5myc-CB3SH3-
(wild-type), pRK5myc-CB3SH3-R356Q, pRK5myc-CB3SH3-R290H
(XLID mutants) or pRK5myc-CB3SH3-R356N/R357N (artificial
phosphoinositide binding site mutant, Reddy-Alla et al.,
2010) using JetPrime transection reagent (Polyplus; 2 µl/µg
DNA). After 48 h, transfected cells were solubilized in a
buffer containing 0.5% (v/v) Nonidet P-40, 150 mM NaCl,
50 mM Tris pH 7.4 and protease inhibitor cocktail (Sigma).
Insoluble material was removed by centrifugation at 16,100× g
for 20 min. Phosphatidylinositol-3-phosphate (PI3P/PtdIns3P)
agarose beads (40 µl; Eschelon Biosciences) were incubated
with cell lysates for 2 h at 4◦C, followed by washing four
times in buffer. Proteins were eluted from beads by heating
at 98◦C for 3 min in 2× sample loading buffer and then
subjected to SDS-PAGE. Proteins binding to beads were detected
by Western blotting using mouse anti-c-myc antibody (Sigma,
1:1000) and HRP-conjugated goat anti-mouse (Santa Cruz,
1:2000). Immunoreactivity was visualized using West Pico
Chemiluminescent Substrate (Pierce). Quantification of PI3P
pulldown assay results for myc-CB3SH3-, myc-CB3SH3-R356Q,
myc-CB3SH3-R290H and myc-CB3SH3-R356N/R357N was performed
in triplicate and differences in PI3P binding were assessed using
an unpaired, two-tailed Student’s t-test.
In vitro Gephyrin Clustering Assays
These were performed essentially as previously described (Long
et al., 2016). HEK293 cells were co-transfected with the
pRK5myc-hCB3SH3-R356Q construct at a 1:1 ratio with pEGFP-
gephyrin using electroporation (Gene Pulser II, Bio-Rad). Cells
were fixed after 24 h for 2 min in 4% (w/v) PFA in PBS.
Immunostaining to detect collybistin was performed using a
mouse anti-c-myc antibody (1:200, Sigma) and detected using
an AlexaFluor 546 goat anti-mouse secondary antibody (1:600;
Invitrogen). Counterstaining for cell nuclei was performed with
DAPI (1:500; Life Technologies). Confocal microscopy was
performed using a Zeiss LSM 710 META. All images were taken
with a×63 objective.
Neuronal Cell Culture, Transfections and
Immunofluorescence
The sheep anti-GAD (lot 1440-4) antibody was a gift from
Dr. Irwin J. Kopin (NINDS, Bethesda, MD, USA). This
antibody, raised against purified rat GAD, recognizes a
65-kDa protein in rat brain immunoblots. The antibody
precipitated GAD from rat brain and detected purified GAD
in crossed immunoelectrophoresis (Oertel et al., 1981). The
Rb antibody to gephyrin (catalog # 261003) was from Synaptic
Systems (Gottingen, Germany). The mouse mAb to cMyc
was from Millipore (Temecula, CA; clone 4A6, catalog
no.05–724). Fluorophore-labeled species-specific anti-IgG
cross-adsorbed secondary antibodies were made in donkey. The
fluorescein isothiocyanate (FITC), or aminomethylcoumarin
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were from Jackson ImmunoResearch Laboratories, West
Grove, PA and the AlexaFluor 594 was from Invitrogen.
Hippocampal (HP) neuronal cultures were prepared according to
Goslin et al. (1998) as described elsewhere (Christie et al.,
2002a,b; Christie and De Blas, 2003). Briefly, dissociated
neurons from embryonic day 18 (E18) rat hippocampi were
plated (10,000–20,000 cells per 18 mm diameter coverslip) and
maintained in rat glial cell conditioned medium. HP neurons
(10 DIV) cultures were transfected with 1 µg of plasmid using
the CalPhos Mammalian Transfection Kit (BD Biosciences, San
Jose, CA, USA), according to the instructions provided by the
manufacturer. Cultures were fixed 72 h later, permeabilized
and subjected to immunofluorescence as described elsewhere
(Christie et al., 2002a,b; Li et al., 2010, 2012; Chiou et al.,
2011; Fekete et al., 2015). Fluorescence images of cultured
hippocampal neurons were collected using a Nikon Plan Apo
60×/1.40 objective on a Nikon Eclipse T300 microscope with a
Photometrics CoolSNAP HQ2 CCD camera driven by IPLab 4.0
(Scanalytics, Rockville, MD) acquisition software. Images were
processed with Photoshop 7.0 (Adobe, San Jose, CA), adjusting
brightness and contrast, as described elsewhere (Christie et al.,
2002b; Li et al., 2005).
Molecular Dynamics Simulations
Molecular dynamics (MD) simulations were performed using
the GROMACS engine, version 2016.1 in conjunction with the
GROMOS54A7 force field (Schmid et al., 2011; Abraham et al.,
2015). The coordinates and parameters for PI3P were developed
using the Automated Topology Builder (ATB) and Repository
(Malde et al., 2011; Koziara et al., 2014) and are available for
download from the ATB (molecule ID: 294885). The coordinates
for the open conformation, wild-type collybistin (CB1SH3-)
were taken from the protein data bank (PDB ID: 4MT7).
The p.R356Q substitution was introduced computationally to
produce a structural model of the collybistin mutant p.R356Q
(collybistinR356Q). The PI3P head group was docked to both
wild-type and mutant collybistin using Autodock vina (Trott
and Olson, 2010) in the vicinity of R356, to provide a range of
putative interaction conformations. The lowest energy docked
conformation was used as a template to rebuild the intact
PI3P molecule prior to MD simulations. Two separate systems
were used to initiate MD simulation: PI3P complexed with
wild-type collybistin and PI3P complexed with collybistinR356Q.
Each system was explicitly solvated with SPC water molecules
and Na+ counter-ions were added to ensure the overall charge
neutrality of the system. A detailed description of the system
set-up is provided as Supplementary Information. After energy
minimization and equilibration, each system was simulated in
triplicate for 200 ns. Following MD simulation, the triplicate
simulations from the PI3P/collybistin system were combined to
give a 600 ns trajectory containing 1,200 frames. Cluster analysis
was performed on the backbone structure of the collybistin
protein using the clustering algorithm described by Daura et al.
(1999). Protein conformations were grouped using a 2.5 Å
distance cut-off. Here, two conformations were considered to
fall within the same cluster if the backbone RMSD between the
conformations was less than the specified cut-off of 2.5 Å. This
procedure was repeated for the PI3P/collybistinR356Q system. The
central (median) conformation from the top two most populated
conformational clusters for the PI3P/collybistin system and
the PI3P/collybistinR356Q system were taken as representative
conformations of PI3P-bound collybistin and collybistinR356Q.
Protein residues within 3 Å of PI3P were considered binding
residues and were determined using the Visual Molecular
Dynamics (VMD) software (Humphrey et al., 1996).
RESULTS
Identification of a p.R356Q Mutation in
ARHGEF9
The three affected males from this family presented with mild NS
XLID (Figure 1A) without seizures, neurologic, ocular or other
phenotypes. X-chromosome exome resequencing of individual
II:8 followed by bioinformatics analysis and filtering against
public datasets revealed four novel missense changes: ARHGEF9,
chrX:62875607C>T, p.R356Q (Figures 1B–D), consensus score
5.13, predicted as probably damaging (PolyPhen-2; Adzhubei
et al., 2013) and damaging (SIFT; Kumar et al., 2009) with
a CADD score (Kircher et al., 2014) of 26; CCDC22, chrX:
49105321A>G, p.A492G with a conservation score of 5.56 and
predicted as benign (Polyphen-2) and tolerated (SIFT) and
CADD of 18; FAM3A, chrX:153736880T>C, p.E37G with a
conservation score 2.67 and predicted as benign and tolerated
and CADD of 15; GLUD2, chrX:120181572T>C, p.S12P with
a low conservation score (0.06) and predicted as benign and
damaging with a CADD score of 11. This strongly suggested that
one of the novel missense variants identified in the established
XLID genes ARHGEF9 (Harvey et al., 2004; Marco et al., 2008;
Kalscheuer et al., 2009; Lesca et al., 2011; Shimojima et al., 2011;
Lemke et al., 2012; de Ligt et al., 2012; Long et al., 2016; Alber
et al., 2017; Klein et al., 2017; Wang et al., 2018) and CCDC22
(Voineagu et al., 2012; Kolanczyk et al., 2015) or a combination
of both could be responsible for XLID in this family. Subsequent
segregation analysis using Sanger DNA sequencing indicated
that both variants were present in the three affected males
(Figures 1A–D), and in heterozygous form in their mother,
whereas the unaffected brother did not have these variants. Thus,
both variants co-segregated with the XLID phenotype in all
individuals tested. We subsequently performed functional assays
on the ARHGEF9 missense mutation, which had the highest
CADD score.
XLID Mutation p.R356Q Disrupts PH
Domain—PI3P Interactions and
Collybistin-Mediated Gephyrin Clustering
in Cellular Assays
Collybistin has a multi-domain structure consisting of a
regulatory SH3 domain, a catalytic RhoGEF domain and a
PH domain (Figure 1E). Substitution p.R356Q is the first
reported ARHGEF9 missense mutation affecting a highly-
conserved phosphoinositide-binding residue in the PH domain
(Figure 1F). In order to determine whether the p.R356Q
mutation affected collybistin binding to PI3P, we performed
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FIGURE 1 | Identification of a p.R356Q mutation in ARHGEF9 in family D228. (A) Pedigree of the D228 family. Open symbols represent normal individuals, filled
squares represent affected males. Individuals who are deceased have a slash through the symbol. Individuals tested for the nucleotide substitution in each family are
indicated with either a T (mutant allele) or a C (normal allele). (B–D) DNA sequence electropherograms for the chrX:62875607C>T, p.R356Q variant reported in this
study, showing wild-type, hemizygous and heterozygous states. (E) Schematic of the human collybistin protein with a regulatory SH3 domain, a catalytic RhoGEF
domain and a pleckstrin homology (PH) domain. The relative locations of known missense and nonsense variants in ARHGEF9 are shown. (F) Sequence alignments
of collybistin proteins from various species showing the high conservation of R356 in the PH domain. R356 is one of two predicted PI3P binding residues (R356 and
R357, green highlighting).
pulldown assays (Figures 2A,B) using PI3P immobilized on
agarose beads incubated with lysates of HEK293 cells transfected
with either tagged wild-type collybistin (myc-CB3SH3-), the
new mutant myc-CB3SH3-R356Q, a known human XLID mutant
known to be deficient in PI3P binding (myc-CB3SH3-R290H;
Papadopoulos et al., 2015) or an artificial phosphoinositide
binding site mutant myc-CB3SH3-R356N/R357N (Reddy-Alla et al.,
2010). A significant reduction of PI3P binding was observed
for myc-CB3SH3-R356Q (7.62 ± 0.97), myc-CB3SH3-R290H
(8.73 ± 0.79) and myc-hCB3SH3-R356N/R357N (3.41 ± 0.85)
compared to wild-type collybistin (Figures 2B,C; pull-down
fraction ± SEM, n = 3, p < 0.0001, unpaired student’s t-test).
Given the key role of collybistin in gephyrin clustering at
inhibitory synapses, we also investigated whether the p.R356Q
substitution influenced collybistin-mediated translocation
of EGFP-gephyrin to submembrane microaggregates in a
cellular clustering assay (Harvey et al., 2004; Kalscheuer et al.,
2009; Long et al., 2016). Collybistin variants containing the
regulatory SH3 domain (e.g., myc-CB3SH3+) typically co-localize
with EGFP-gephyrin in large intracellular aggregates (Kins
et al., 2000; Harvey et al., 2004; Kalscheuer et al., 2009; Long
et al., 2016) and require neuroligin 2/4, GABAAR α2 or
the GTPase TC10 for activation (Poulopoulos et al., 2009;
Saiepour et al., 2010; Mayer et al., 2013). By contrast, variants
lacking the N-terminal SH3 domain (e.g., myc-CB3SH3-) result
in the formation of submembrane EGFP-gephyrin clusters
(Kins et al., 2000; Harvey et al., 2004; Kalscheuer et al.,
2009; Long et al., 2016; Figures 2D–G). On co-expression
with EGFP-gephyrin, myc-CB3SH3-R356Q was not capable
of forming submembrane microaggregates, but co-localized
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FIGURE 2 | R356Q reduces collybistin PI3P binding and gephyrin cluster formation in cellular assays. (A,B) Human embryonic kidney 293 (HEK293) cells were
transfected with plasmids encoding myc-CB3SH3- (wild-type, WT), myc-CB3SH3-R356Q (R356Q), myc-CB3SH3-R290H (R290H) or myc-CB3SH3-R356Q (R356N/R357N)
and cell lysates were incubated with PI3P-conjugated agarose beads. After washing, bound material was subjected to SDS-PAGE and analyzed by immunoblotting
with an anti-myc antibody (Sigma). No significant differences were observed in total level of myc-CB3SH3-R356Q, myc-CB3SH3-R290H or myc-CB3SH3-R356N/R357N
expression in comparison with myc-CB3SH3- (left panel, 5% input protein). However, myc-CB3SH3-R356Q myc-CB3SH3-R290H and myc-CB3SH3-R356N/R357N binding to
PI3P was significantly reduced (right panel, PI3P bead pull-down). (C) Quantification of PI3P pull-down assays normalized to wild-type myc-CB3SH3-:
myc-CB3SH3-R290H: 8.73 ± 0.79, 1.37; myc-CB3SH3-R356Q: 7.62 ± 0.97, 1.68; myc-hCB3SH3-R356N/R357N: 3.41 ± 0.85, 1.47; pull-down fraction ± SEM, SD; n = 3,
∗∗∗ p < 0.0001, unpaired student’s t-test. (D–K) HEK293 cells were co-transfected with EGFP-gephyrin and either wild-type myc-CB3SH3- or mutant
myc-CB3SH3-R356Q, immunostained using anti-myc and AlexaFluor 546 antibodies and co-stained with a nuclear marker (DAPI). Note that while wild-type
myc-CB3SH3- (red) co-localizes with gephyrin (green) in submembrane microaggregates (D–G), mutant myc-CB3SH3-R356Q (red) co-localizes with EGFP-gephyrin
(green) in elongated cytoplasmic aggregates (H–K), consistent with a lack of CB-mediated gephyrin clustering activity for the p.R356Q mutant. Scale bar = 10 µm.
with EGFP-gephyrin in elongated cytoplasmic aggregates
(Figures 2H–K). This distribution is similar to that previously
observed for collybistin variants lacking the PH domain
(Harvey et al., 2004) or containing missense mutations
that disrupt PI3P binding, such as p.R290H, p.R338W and
p.R356N/R357N (Reddy-Alla et al., 2010; Papadopoulos et al.,
2015; Long et al., 2016). These results demonstrate that the
p.R356Q substitution disrupts both collybistin PI3P binding
and collybistin-mediated accumulation of EGFP-gephyrin in
submembrane microclusters.
Collybistin Phosphoinositide Binding
Mutants p.R356Q and p.R356N/R357N
Alter Gephyrin Cluster Number and Size in
Cultured Hippocampal Neurones
To assess the impact of the p.R356Q mutation on collybistin-
mediated neuronal gephyrin clustering, we overexpressed either
wild-type myc-CB3SH3-, myc-CB3SH3-R356Q or the artificial PI3P
binding mutant myc-CB3SH3-R356N/R357N in primary cultures
of rat hippocampal neurons. Previous studies in this neuronal
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FIGURE 3 | Collybistin phosphoinositide binding mutants R356Q and R356N/R357N alter gephyrin cluster number and size in cultured hippocampal neurones.
Triple-label immunofluorescence of transfected hippocampal neurons with mouse anti-myc (green), rabbit anti-gephyrin (red) and sheep anti-GAD (blue).
(A–C) Transfection with myc-CB3SH3- (wild-type, WT). (D–F) Transfection with myc-CB3SH3-R356Q (R356Q). (G–I) Transfection with myc-CB3SH3-R356N/R357N
(R356N/R357N). The two panels on the right side of each row correspond to the boxed areas in (A,D,G), respectively. Arrows point to GABAergic synapses.
Arrowheads point to aggregates of gephyrin that form in transfections with collybistin R356Q or R356N/R357N. Note that there is colocalization of mutant collybistin
and gephyrin in these aggregates. Wild-type collybistin does not induce the formation of aggregates but accumulates at GABAergic synapses and colocalizes with
gephyrin (arrows, panel C). The R356Q and the R356N/R357N mutants do not accumulate at synapses (arrows, panels F,I). The R356N/R357N mutant (panels H,I)
shows a clear decrease in the overall number of gephyrin clusters, including synaptic gephyrin clusters. In neurons overexpressing the R356N/R357N mutant, GAD
positive puncta often make contacts without apposed gephyrin clusters (crossed arrows). Scale bar = 26 µm for (A,D,G) and 10 µm for (B,C,E,F,H,I).
expression system have shown that wild-type recombinant
collybistin isoforms (e.g., CB2SH3+, CB2SH3-, CB3SH3+, and
CB3SH3-) target to and concentrate at GABAergic postsynapses
(Chiou et al., 2011). Notably, isoforms lacking the SH3 domain
(e.g., CB2SH3- and CB3SH3-) induce the formation of synaptic
gephyrin superclusters (Chiou et al., 2011; Fekete et al., 2017)
that are accompanied by a significant increase in the amplitude
of miniature inhibitory postsynaptic currents (mIPSCs). In this
study, we utilized triple-label immunofluorescence with mouse
anti-myc, rabbit anti-gephyrin and sheep anti-GAD to reveal
exogenous wild-type and mutant collybistin, native gephyrin and
GAD, respectively (Figures 3A–C). As expected, overexpressed
wild-type collybistin (myc-CB3SH3-; Figures 3A–C) accumulated
at GABAergic synapses, colocalizing with gephyrin and GAD65
(Figures 3B,C, arrows). By contrast, overexpression of myc-
CB3SH3-R356Q and myc-CB3SH3-R356N/R357N (Figures 3D–I)
resulted in the formation of non-synaptic aggregates
(Figures 3D–I, arrowheads) characterized by a circular shape
and bright fluorescence. Mutant myc-CB3SH3-R356Q and
myc-CB3SH3-R356N/R357N in these aggregates co-localized with
gephyrin (see, e.g., Figure 3D, lower panels) but did not associate
with GAD-positive terminals (Figures 3D–I). Hence, myc-
CB3SH3-R356Q and myc-CB3SH3-R356N/R357N do not accumulate at
inhibitory synapses (arrows in Figures 3F,I). We also noted that
in neurons overexpressing the myc-CB3SH3-R356N/R357N mutant,
GAD-positive puncta often make contacts without apposed
gephyrin clusters (Figure 3H, crossed arrows)—an effect that
was not seen for myc-CB3SH3- or myc-CB3SH3-R356Q.
We also assessed the effect of wild-type andmutant collybistin
isoforms on synaptic gephyrin cluster density (Figure 4A)
and size (Figure 4B), excluding the large non-synaptic
gephyrin/mutant aggregates (for myc-CB3SH3-R356Q and myc-
CB3SH3-R356N/R357N) from this analysis. No significant differences
in cluster density were observed comparing non-transfected
neurones with those expressing wild-type myc-CB3SH3- (non-
transfected = 9.33 ± 0.33 vs. myc-CB3SH3- = 8.73 ± 0.88;
mean clusters/100 µm2 ± SEM). However, gephyrin cluster
density was significantly decreased for myc-CB3SH3-R356Q
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FIGURE 4 | Quantification of gephyrin cluster number and cluster size for wild-type collybistin and mutants R356Q and R356N/R357N in cultured hippocampal
neurones. (A) To quantify the effect of these mutants, we measured gephyrin cluster density/100 µm2 in non-transfected neurones (NT = 9.33 ± 0.33, 1.04) and
neurones transfected with wild-type collybistin (WT = 8.73 ± 0.88, 2.77) and collybistin phosphoinositide binding mutants (R356Q = 6.42 ± 0.52, 1.65;
R356N/R357N = 3.37 ± 0.63, 1.99; mean ± SEM, SD). The gephyrin cluster density was decreased for R356Q but not as much as for R356N/R357N, ∗p < 0.05;
∗∗∗p < 0.001 for each mutant respectively compared with either NT or WT, n = 10 neurons each. The total number of clusters counted for density were 283, 273,
189 and 99 for NT, WT, R356Q and R356N/R357N, respectively. For quantification of cluster density, two independent transfections were made for each construct,
and all constructs were used in each experiment. A total of 60 dendritic fields (50 µm2 each) per construct from 10 randomly selected neurons
(10 neurons/construct, 3 dendrites/neuron, 2 dendritic fields/dendrite) were analyzed. (B) Gephyrin cluster size was NT = 0.095 ± 0.003, 0.011;
WT = 0.240 ± 0.024, 0.076; R356Q = 0.132 ± 0.008, 0.026; R356N/R357N = 0.129 ± 0.016, 0.051. Values are mean ± SEM, SD / µm2, n = 10 neurons each.
For quantification of cluster size, two independent transfections were made for each construct, and all constructs were used in each experiment. ∗∗∗p < 0.001 for
WT with each of the other plasmids; ∗∗p < 0.01 for R356Q compared with NT indicates a slight increase in cluster size in this mutant. The total number of clusters
counted for size were 680, 584, 492 and 180 for NT, WT, R356Q and R356N/R357N, respectively. No significant difference was observed for R356N/R357N
compared with NT or R356Q. The data were analyzed by one-way analysis of variance with a Tukey-Kramer multiple comparisons test.
(6.42 ± 0.52 clusters/100 µm2) with a further decrease for myc-
CB3SH3-R356N/R357N (3.37 ± 0.63 clusters/100 µm2). As expected
from previous studies (Chiou et al., 2011), synaptic gephyrin
cluster size was significantly increased on overexpression of
myc-CB3SH3- (non-transfected = 0.095 ± 0.003 vs. wild-type
myc-CB3SH3- = 0.240 ± 0.024; mean clusters µm2 ± SEM).
However, only a slight increase in cluster size was observed for
myc-CB3SH3-R356Q (0.132± 0.008) with no significant difference
observed for myc-CB3SH3-R356N/R357N (0.129 ± 0.016) compared
non-transfected neurones.
Molecular Dynamics Simulations Reveal
That Wild-Type Collybistin and
CollybistinR356Q Display Distinct
Conformations That May Underlie
Observed Differences in PI3P Binding
MD simulations revealed that both wild-type and mutant
collybistinR356Q adopted a range of conformations that could
be grouped into two distinct conformational clusters. These
differed from the reported crystallographic conformation of
wild-type collybistin and the mutant collybistinR356Q model
with docked PI3P (Figures 5A,B), which were used as starting
structures to initiate the simulations. Cluster analysis of
wild-type collybistin showed that it adopted a more elongated
conformation for approximately 68% (814 out of 1200 structures)
and an ‘‘open clam’’ conformation for approximately 32%
(380 out of 1200 structures) of the combined trajectory. The
central conformations of each are shown in Figures 5C,E,
respectively. Cluster analysis of collybistinR356Q also revealed
two distinct conformations during the combined trajectories,
that differed from the conformations adopted by wild-type
collybistin. CollybistinR356Q predominantly displayed a ‘‘side
saddle’’ conformation for 64% (Figure 5D, 769 out of
1,200 structures) and a ‘‘shut clam’’ conformation for 31%
(Figure 5F, 373 out of 1,200 structures) of the combined
simulation trajectory. During MD simulations, both the position
and orientation of the PI3P molecule changed significantly
from its initial docked location in both wild-type collybistin
and collybistinR356Q simulations (Figures 5A,B, respectively),
binding to a unique site in the PHdomain in each conformational
cluster, as shown in Figure 5. Table 1 and Figure 6 show that
there was little overlap in the residues that bind PI3P in each
of the predominant conformational clusters. There was more
overlap in the PI3P-binding residues in the starting conformation
of collybistinR356Q and its two predominant conformational
clusters than in the representative conformations than for
wild-type collybistin. Intriguingly, in the second most populated
conformational cluster of wild-type collybistin, PI3P moves far
from the initial docked location to bind in the deep binding cleft
of the ‘‘open clam’’ conformation shown in Figures 5E, 6E.
DISCUSSION
This study reports the identification and functional
characterization of a novel PH domain mutation (p.R356Q) in
the RhoGEF collybistin that is likely to represent the cause of
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 March 2019 | Volume 12 | Article 60
Chiou et al. ARHGEF9 p.R356Q Mutation in XLID
TABLE 1 | The PI3P-binding residues in molecular dynamics simulations of
wild-type collybistin and collybistinR356Q.
Putative PI3P-binding residues
Wild-type
collybistin
collybistinR356Q
Crystal structure K408 Q337
R357
Most prevalent conformation (∼60%) A326 Q337
N335 R338
Q336 K351
Q337 K352
F406 D353
K408 L354
R357
Second most prevalent conformation (∼30%) Y332 Q218
N335 Q222
F384 K351
M388 D353
K389 L354
I355
R357
XLID in this family. Using X-exome sequencing, bioinformatics
analysis and inheritance testing, we found a novel SNV
(chrX:62875607C>T, p.R356Q) in ARHGEF9 that segregated
with the disease phenotype. This substitution of a highly
conserved functionally important residue in the PH domain
had a consensus score of 5.13, and was predicted as probably
damaging and damaging by PolyPhen-2 and SIFT, with a CADD
score of 26. Although we did not exclude a further potential
variant in CCDC22, a gene that has previously been linked to
ID, this substitution was predicted as benign and tolerated by
Polyphen-2 and SIFT and had a lower CADD score of 18. It
is also noteworthy that missense mutations in CCDC22 are
associated with Ritscher-Schinzel syndrome-2 (Kolanczyk et al.,
2015) an X-linked recessive syndromic form of ID associated
with posterior fossa defects, cardiac malformations, and minor
abnormalities of the face and distal extremities. These additional
phenotypic features have not been observed in the family under
study to date.
Using multiple biochemical and cellular functional assays,
we were able to establish the likely pathomechanism for
collybistin p.R356Q—a reduction in PI3P binding in pulldown
assays, leading to a loss of gephyrin clustering activity in
an in vitro EGFP-gephyrin clustering assay (Harvey et al.,
2004). It is noteworthy that collybistin constructs tested in this
study represent CB3SH3-, i.e., lack the N-terminal SH3 domain,
because isoforms containing the SH3 domain do not show
EGFP-clustering activity in HEK293 cells without the addition
of additional regulatory proteins such as neuroligin 2 or
the GABAAR α2 subunit (Harvey et al., 2004; Poulopoulos
et al., 2009; Saiepour et al., 2010). In the absence of these
interactors, collybistin isoforms harboring the N-terminal
SH3 domain (e.g., CB3SH3+) adopts a closed and autoinhibited
conformation that prevents the PH domain from binding to
phosphoinositides (Ludolphs et al., 2016). Hence, we used
CB3SH3- rather than CB3SH3+ in our PI3P pull-down and cellular
FIGURE 5 | Wild-type collybistin and collybistinR356Q adopt two distinct
conformations in solution with unique PI3P binding sites. PI3P (shown in
space-fill representation, colored by atom where carbon = tan, oxygen = red,
nitrogen = blue, hydrogen = white and phosphorous = purple) is docked to
wild-type collybistin (A) and collybistinR356Q (B) structures (collybistin is shown
as a purple and blue surface). Representative collybistin conformations and
PI3P binding poses from the most frequently adopted conformations during
molecular dynamics simulations are shown in panels (C–F). A 2.5 Å cut-off
distance was used to perform the cluster analysis and the proportion of the
simulation that each conformation represents is labeled. Key arginine residues
R338, R357 and R356 are colored orange (R338 and R357) and gray (R356).
clustering assays. In cultured hippocampal neurones, all tested
collybistin isoforms (CB2SH3+, CB2SH3-, CB3SH3+ and CB3SH3-)
target to and concentrate at GABAergic postsynapses (Chiou
et al., 2011; Fekete et al., 2017) with the major difference
being that transfection of de-regulated isoforms that lack the
SH3 domain (e.g., CB3SH3-) results in large postsynaptic gephyrin
and GABAA receptor superclusters, while isoforms containing
the SH3 domain induce the formation of supernumerary
non-synaptic clusters (Chiou et al., 2011; Fekete et al., 2017).
In this system, overexpression of the myc-CB3SH3-R356Q mutant
resulted in a decrease in the overall number of synaptic
gephyrin clusters compared to controls. Notably, p.R356Q
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FIGURE 6 | Predicted PI3P-binding residues in wild-type collybistin and collybistinR356Q. Predicted PI3P binding residues in the protein conformation obtained from
PI3P docking to (A) the wild-type collybistin crystal structure (PDB ID: 4MT7) and (B) the computational model of the collybistinR365Q mutation. PI3P binding residues
from MD simulations of the most populated conformational cluster of (C) wild-type collybistin and (D) collybistinR365Q. PI3P binding residues from MD simulations of
the second most populated conformational cluster of (E) wild-type collybistin and (F) collybistinR365Q. The PH and RhoGEF domains are shown in transparent
gray-blue and mauve, respectively. R357 and R338 are shown in gold licorice. R556 and R356Q are shown as gray licorice. The PI3P lipid is shown as a
ball-and-stick model, colored by atom (carbon = tan, oxygen = red, nitrogen = blue, hydrogen = white and phosphorous = purple). The PI3P-binding residues, taken
as those within 3 Å of the PI3P molecule, are shown in stick representation, colored by atom (carbon = yellow, oxygen = red, nitrogen = blue, hydrogen = white,
pink = resonance structure). Key arginine residues that impact phosphoinositide binding, including R338 (Long et al., 2016), R356 and R357 (Reddy-Alla et al., 2010)
are shown as sticks and are colored orange (R338 and R357) and gray (R356). All residues shown are labeled, with binding residues labeled with black lettering.
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also abrogated the ability of myc-CB3SH3- to form gephyrin
superclusters (Chiou et al., 2011; Fekete et al., 2017). Taken
together, our analysis strongly suggests that the collybistin
p.R356Q variant is responsible for the mild intellectual disability
observed in this family—due to disruption of collybistin PI3P
binding, leading to a decrease in synaptic gephyrin and GABAA
receptor clustering.
A number of mutations in ARHGEF9 have been identified
in patients encompassing missense and nonsense mutations,
deletions and complex rearrangements (Long et al., 2016; Alber
et al., 2017). As noted by recent reviews aimed at correlating
genotypes and patient phenotypes (Alber et al., 2017; Wang
et al., 2018), the associated patient phenotypes vary quite
substantially. Individuals with mutations inARHGEF9 present in
early childhood, with delayed motor development sometimes in
combination with seizures. Intellectual disability generally ranges
from moderate to severe, although males with severe intellectual
disability often have intractable epilepsy and facial dysmorphism,
including enlarged, fleshy earlobes, a sunken appearance of
the middle face in combination with a protruding of the jaw
(Alber et al., 2017). Curiously, several patients with mutations
affecting the PH domain (p.R338W, Long et al., 2016; p.E400K,
de Ligt et al., 2012; p.R356Q, this study) appear to have mild
or moderate XLID and do not develop seizures. A further PH
domain mutation close to the RhoGEF-PH linker, p.G323R, also
resulted in a low frequency of delayed onset febrile and afebrile
seizures (Klein et al., 2017).
So why do PH domain mutations appear to have less
impact? There are several possibilities as to why this might
be the case. Certainly, mutations that affect the N-terminal
SH3 domain have the potential to be extremely deleterious,
either unlocking collybistin into a conformationally ‘‘open’’
state (Soykan et al., 2014; Ludolphs et al., 2016), or disrupting
key synaptic interactors. For example, the collybistin mutation
p.G55A associated with early infantile epileptic encephalopathy
and severe psychomotor retardation has a clear dominant-
negative effect, causing gephyrin aggregation in neurons and
subsequent loss of synaptic gephyrin and GABAA receptor
clusters (Harvey et al., 2004). The p.G55A mutation also disrupts
collybistin interactions with key synaptic molecules that interface
with the SH3 domain, including neuroligin 2 (Poulopoulos
et al., 2009) and GABAA receptor α2 subunit (Saiepour et al.,
2010). By contrast, mutations found in the RhoGEF domain
could potentially affect GDP-GTP exchange on the small GTPase
Cdc42 (Reddy-Alla et al., 2010), gephyrin binding (Xiang
et al., 2006) or alter the strength of intramolecular interactions
RhoGEF and PHdomains, as in the case of the p.R290Hmutation
(Papadopoulos et al., 2015) that indirectly affected PI3P binding.
To date, two of the reported PH domain mutations (p.R338W,
Long et al., 2016; p.R356Q, this study) appear to operate by
reducing the affinity of collybistin for phosphoinositides such
as PI3P, although interactions with the small Rho-like GTPase
TC10—which also binds to the collybistin PH domain (Mayer
et al., 2013)—have not yet been assessed. Our MD simulations
show that wild-type collybistin adopted at least two distinct
conformations in solution (Figures 5C,D). These are distinct
from the two conformations adopted by mutant collybistinR356Q
(Figures 5E,F). Furthermore, PI3P did not remain bound at the
docking location during the simulations, but instead bound in
unique locations on the PH domain that depended on the protein
conformation (Figure 6). Our MD results suggest that the range
of conformations adopted by wild-type collybistin are likely to be
impacted by the p.R356Q variant, and hence affect PI3P binding.
Indeed, there was little overlap in the PI3P-binding residues
for wild-type collybistin, as shown in Table 1 and Figure 6.
However, residue Q337 bound PI3P in both of themost prevalent
conformations of collybistin and is likely to be an important
PI3P-binding residue.
Although the p.R356Q and p.R338W substitutions completely
inhibit collybistin-mediated gephyrin clustering in cellular
models (Figure 2; Long et al., 2016), the effects observed for
p.R356Q in primary neurones were more modest. Although
overexpression of myc-CB3SH3-R356Q resulted in the formation
of non-synaptic collybistin-gephyrin aggregates, CB3SH3-R356Q
was not able to localize to synaptic sites and is therefore
unlikely to have dominant-negative effects. Rather, CB3SH3-R356Q
modestly reduced synaptic gephyrin cluster density, without
affecting cluster size (Figure 3). Under these circumstances,
we would predict that missense mutations in the collybistin
PH domain that disrupt PI3P binding will show milder disease
course than dominant-negative collybistin mutations in the
SH3 or RhoGEF domains that substantially reduce gephyrin
cluster number and size, so disrupting associated inhibitory
GABAergic transmission.
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